Sign inJoin waitlistJoin the waitlist

Robert Brodsky

Director, Hematology T32 · Johns Hopkins University School of Medicine

Credentials: · · ·

History

Hematology T32 · Johns Hopkins University School of Medicine
Present

Medical Oncology
1993–1995
Hematology
1992–1993
Internal Medicine
1989–1992
HAHNEMANN UNIV SCH OF MED, PHILADELPHIA
1985–1989

Research

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Biology of Blood and Marrow Transplantation · 2008 · 1,627 citations
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
New England Journal of Medicine · 2006 · 994 citations
Cyclophosphamide and cancer: golden anniversary
Review · Nature Reviews Clinical Oncology · 2009 · Last of 3 authors · 770 citations

EF
Ephraim Fuchs
41 papers
JM
Javier Meade
38 papers
RA
Richard Ambinder
38 papers
Leo Luznik
37 papers
CH
Carol Huff
33 papers
AD
Amy DeZern
32 papers · 3 as a fellow
William Matsui
32 papers · 1 as a fellow
IB
Ivan Borrello
29 papers
DG
Douglas Gladstone
27 papers
LS
Lode Swinnen
27 papers
SC
Shruti Chaturvedi
27 papers · 1 as a fellow
BS
Bruce Smith
23 papers

Grants

Training Program in Hematology
National Heart, Lung, and Blood Institute · T32
Contact PI · $4.8M · Johns Hopkins University
1982–2030
Initiation of a Cohort to Define Pathogenic Mechanisms, Precision Diagnosis And Complications of Thrombotic Microangiopathies: The IMPACT Study
National Heart, Lung, and Blood Institute · U54
Contact PI · $3.1M · Johns Hopkins University
2025–2030
Complementopathies: Biology, Biomarkers, and Targets
National Heart, Lung, and Blood Institute · R56
Contact PI · $368.4K · Johns Hopkins University
2022–2024
Complementopathies: Genotype and Phenotype
National Heart, Lung, and Blood Institute · R01
Contact PI · $2M · Johns Hopkins University
2016–2022

Clinical trials

Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia
Principal investigator · Terminated · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2011–2014
High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
Principal investigator · Withdrawn · Phase 2
Johns Hopkins University
2010
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
Study chair · Completed · Phase 2
Johns Hopkins University
1999
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
Study chair · Completed
Johns Hopkins University
1997